01 What is MK-677?
In plain English.
MK-677, also called ibutamoren, is a lab-made drug developed in the mid-1990s by Merck. It tells the pituitary to release a pulse of growth hormone by binding the ghrelin receptor, the same receptor used by the body's "hunger hormone." Unlike most GH-axis compounds in the wellness world, it is taken orally as a capsule or liquid, not injected.
Important classification note: MK-677 is not strictly a peptide. It's a non-peptidic small molecule that mimics what peptide GHRPs (ipamorelin, GHRP-6) do at the same receptor. We profile it because everyone searching for "peptides for muscle / GH" finds it instantly, sold alongside true peptides, stacked with them, and often described as one. Treating it as a peptide is sloppy; understanding it sits on the same axis is fair.
02 How it works
The simple version, then the science.
MK-677 binds the growth hormone secretagogue receptor (GHS-R1a) on pituitary cells, the same receptor ghrelin uses. That signal triggers a pulse of growth hormone (GH), which drives the liver to make IGF-1, the downstream signal most of GH's muscle, bone and metabolic effects flow through. Because it's a small molecule rather than a peptide, it survives the gut and works as a once-daily oral dose.
Go deeper · the proposed mechanism
Mechanistically, MK-677 (L-163,191) is a benzolactam-spiroindoline that acts as a potent, selective agonist at GHS-R1a (Patchett et al. 1995). Receptor activation engages Gq-coupled phospholipase C signalling, IP3 release and calcium-dependent GH release from somatotrophs. In healthy elderly volunteers, daily oral dosing restored 24-hour GH pulsatility and serum IGF-1 to the range seen in healthy young adults (Chapman et al. 1996; Nass et al. 2008). The pharmacology of the GH pulse is well-characterised; the open question has always been whether translating that pulse into months of elevated IGF-1 produces meaningful clinical benefit without metabolic cost.
03 What it's used for
Each use graded by how strong the evidence actually is.
- LimitedGH-deficient & catabolic statesMurphy et al. 1998 showed MK-677 reversed protein catabolism in healthy volunteers on a calorie-restricted diet. Several phase 2 programmes followed in GH-deficient adults; none progressed to approval.
- LimitedAge-related frailty & body compositionNass et al. 2008, a 2-year placebo-controlled trial in 65 healthy older adults, found MK-677 raised lean mass and restored GH/IGF-1 to young-adult levels, but did not improve functional strength or gait endpoints, and raised fasting glucose and HbA1c.
- LimitedHip-fracture recovery in the elderlyAdunsky et al. 2011, a phase 2b multicentre RCT, tested MK-0677 in patients recovering from hip surgery. It raised IGF-1 but did not improve most functional outcomes, and was associated with serious adverse events that led to early termination.
- AnecdotalMuscle, sleep & appetite in adult usersWidely sold as "Nutrobal" in the supplement-adjacent grey market. Users report improved sleep, increased appetite and modest mass gain, mostly water and lean tissue. No controlled trials in this population.
04 What the evidence says
MK-677 has a stronger paper trail than most "research peptide" compounds, and a worse outcome. Merck took it through the lab (Patchett et al. 1995), into healthy elderly volunteers (Chapman et al. 1996), through a catabolic-stress proof-of-concept (Murphy et al. 1998), and on to multi-year RCTs in older adults (Nass et al. 2008) and hip-fracture patients (Adunsky et al. 2011). The pharmacology held up: daily oral dosing reliably raises 24-hour GH and IGF-1 to young-adult levels. The clinical story did not. Lean mass rose modestly; functional strength and gait did not improve meaningfully; fasting glucose, HbA1c and insulin resistance increased; fluid retention was common; and in the frail elderly there were enough cardiovascular safety signals to push the development programme to a halt. The bodybuilding-forum verdict ("it works") and the regulatory verdict ("not worth the metabolic cost") are both true, they're answering different questions.
05 Dosing & administration
Reported in the literature, information not advice.
No approved human protocol exists, because MK-677 was never approved for any indication. The clinical trials used oral doses in the range of 10–25 mg once daily; that is reported information, not a recommendation. The supplement-adjacent grey market sells capsules and liquids of unverified purity and label accuracy. A qualified clinician should be consulted before considering any GH-axis compound.
06 Side effects & safety
The most important real-world finding from the human trials is impaired insulin sensitivity: fasting glucose and HbA1c rose meaningfully in healthy older adults on chronic dosing (Nass et al. 2008), and the effect was large enough that it would push some users into a pre-diabetic range. This is not a vendor scare-story, it is a phase 2 trial result. Other consistently reported effects include water retention, increased appetite, transient muscle aches and mild lethargy. In the frail elderly, the Adunsky hip-fracture trial reported serious adverse events including congestive heart failure signals, part of why that programme was halted. Long-term tumour risk via sustained IGF-1 elevation is a theoretical concern (IGF-1 is mitogenic) and a reason for caution in anyone with active cancer or a cancer history. Products sold as "MK-677" or "Nutrobal" outside the trials are unregulated; purity, dose accuracy and contamination are real risks.
07 Where to buy (research use only)
Vetted on quality and transparency, not an endorsement to use.
08 Legal & regulatory status
- UKNot licensed as a medicine. Sold as a "research chemical" or "SARM-adjacent" supplement, not for human consumption.
- USNot FDA-approved for any indication. Widely sold in the grey market as a "research compound"; FDA has issued warning letters to suppliers marketing it for human use.
- EU / AUS / CANNo approved human medicine containing ibutamoren. Sale for human consumption is unlawful in most jurisdictions; "research use only" framing is standard.
- Sport (WADA)Prohibited at all times under S2, Peptide Hormones, Growth Factors, Related Substances and Mimetics. Growth hormone secretagogues are explicitly named, and MK-677 is a frequent finding in athlete sanctions.
09 Clinical studies & research
Primary sources. Read the science yourself.